Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients.
Methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation by DNA sequencing and MS-PCR, respectively.
Results: Mutations found in IDH1/2 genes totalled 63.4% (N=40) wherein IDH1 mutations were significantly associated with oligidendrioglioma (p=0.005) and astrocytoma (p=0.0002). IDH1mutants presented more, 60.5% in MGMT promoter methylated cases (p=0.03). IDH1 mutant cases had better survival for GBM and oligodendrioglioma (log rank p=0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (HR: 0.59, p=0.031). Combination of both biomarkers showed better prognosis on temozolomide (p<0.05).